ClinicalTrials.gg
CompletedNCT03504488Updated Jan 15, 2025

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

A Phase 1/2 interventional study of CAB-ROR2-ADC and PD-1 inhibitor in Non Small Cell Lung Cancer, Triple Negative Breast Cancer and Melanoma, sponsored by BioAtla, Inc.. Completed at 59 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by BioAtla, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 895 under way, 141 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
885th of 3,001
132 · median 56
Started
2018
with 160 others
Phase 1/2
487 of 3,374
118 open now
Registered
2,013th of 3,374
by date

Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 885th largest by enrollment of the 3,001 interventional ones that give a count, is one of 161 that started in 2018, is one of 487 in phase 1/2, and was the 2,013th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors

Read the detailed description

This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3021, a conditionally active biologic (CAB) ROR2-targeted antibody drug conjugate (CAB-ROR2-ADC) BA3021 in patients with advanced solid tumors.

This study will consist of a dose escalation phase and a dose expansion phase with BA3021 in Phase 1. Phase 2 will study BA3021 alone or in combination with a PD-1 inhibitor.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Triple Negative Breast Cancer
  • Melanoma
  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have or cytologically confirmed locally advanced unresectable or solid tumor and have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse standard therapy.
  • Patients must have .
  • For the dose expansion phase: Patients with locally advanced unresectable or metastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC) and soft tissue sarcoma (STS)
  • Age ≥ 18 years.
  • Adequate renal function
  • Adequate liver function
  • Adequate hematological function
  • Have an (ECOG) performance status of 0 or 1.
  • of at least three months.

Exclusion criteria

Exclusion Criteria:

  • Patients must not have cardiac disease.
  • Patients must not have known non-controlled .
  • Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
  • Patients must not have had major surgery within 4 weeks before first BA3021 administration.
  • Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
  • Patients must not have known (HIV) infection, active and/or .
  • Patients must not be women who are pregnant or breast feeding.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Monotherapy - CAB-ROR2-ADC (BA3021) alone

    BA3021 alone Q2W dosing regimen

    Biological: CAB-ROR2-ADC

  • Experimental
    Combination Therapy

    CAB-ROR2-ADC (BA3021) with PD-1 inhibitor

    Biological: CAB-ROR2-ADC · Biological: PD-1 inhibitor

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1: Safety Profile

    Assess dose limiting toxicity as defined in the protocol

    Time frame: Up to 24 months

  2. Phase 1: Safety Profile

    Assess maximum tolerated dose as defined in the protocol

    Time frame: Up to 24 months

  3. Phase 1 and 2: Safety Profile

    Frequency and severity of AEs and/or SAEs

    Time frame: Up to 24 months

  4. Phase 2: Confirmed Objective Response Rate (ORR)

    Proportion of patients who achieve a confirmed CR or PR

    Time frame: Up to 24 months

Secondary outcomes

  1. Phase 1: Pharmacokinetics

    Plasma concentrations of ADC, total antibody and MMAE

    Time frame: Up to 24 months

  2. Phase 1: Pharmacokinetics

    Peak Plasma Concentration (Cmax)

    Time frame: Up to 24 months

  3. Phase 1: Pharmacokinetics

    Area under the plasma concentration versus time curve

    Time frame: Up to 24 months

  4. Phase 1: Confirmed Objective Response Rate (ORR)

    Proportion of patients who achieve a confirmed CR or PR

    Time frame: Up to 24 months

  5. Phase 1: Immunogenicity

    The number and percentage of patients who develop detectable anti-drug antibodies (ADAs)

    Time frame: Up to 24 months

  6. Phase 1 and 2: Duration of response (DOR)

    Time from the first documented OR until the first documented disease progression or death (due to any cause), whichever occurs first

    Time frame: Up to 24 months

  7. Phase 1 and 2: Progression-free survival (PFS)

    Time from the first dose of IP until the first documentation of disease progression or death due to any cause, whichever occurs first

    Time frame: Up to 24 months

  8. Phase 1 and 2: Best overall response (OR)

    All post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy

    Time frame: Up to 24 months

  9. Phase 1 and 2: Disease control rate (DCR)

    Proportion of patients with a best overall response of confirmed CR, confirmed PR, or stable disease (SD) ≥ 12 weeks

    Time frame: Up to 24 months

  10. Phase 1 and 2: Time to response (TTR)

    Time from the first dose of investigational product until the first documentation of OR

    Time frame: Up to 24 months

  11. Phase 1 and 2: Overall survival (OS)

    Time from the first dose of BA3021 treatment until death due to any cause

    Time frame: Up to 24 months

  12. Phase 1 and 2: Tumor size

    Percent change from baseline in tumor size

    Time frame: Up to 24 months

07

Study locations

59 sites
  • University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • City of Hope - Duarte
    Duarte, California 91010, United States
  • University of California, San Diego (UCSD) - Moores Cancer Center
    La Jolla, California 92093, United States
  • California Research Institute
    Los Angeles, California 90027, United States
  • USC Norris
    Los Angeles, California 90033, United States
  • UC Irvine Medical Center - Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • American Institute of Research
    Whittier, California 90603, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Sarah Cannon Research Institute at Health One
    Denver, Colorado 80218, United States
  • Florida Cancer Specialists & Research Institute
    Fleming Island, Florida 32003, United States
  • Florida Cancer Specialists & Research Institute
    Fort Myers, Florida 33916, United States
  • Memorial Cancer Institute (MCI)
    Hollywood, Florida 33028, United States
  • Florida Cancer Specialist - North
    Saint Petersburg, Florida 34474, United States
  • Memorial Sloan-Kettering Cancer Center
    Tampa, Florida 33612, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Florida Cancer Specialists
    West Palm Beach, Florida 33401, United States
  • Augusta University - Georgia Cancer Center
    Augusta, Georgia 30912, United States
  • Baptist Health Systems
    Lexington, Kentucky 40503, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Norton Cancer Institute, Brownsboro Hospital Campus
    Louisville, Kentucky 40241, United States
  • Hematology/Oncology Clinic
    Baton Rouge, Louisiana 70809, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Comprehensive Cancer Care of Nevada
    Las Vegas, Nevada 89169, United States
  • OptumCare Cancer Care
    Las Vegas, Nevada 89169, United States
  • Roswell Park
    Buffalo, New York 14263, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • FirstHealth Outpatient Cancer Center
    Pinehurst, North Carolina 28374, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • UPMC Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Medical University of South Carolina- Hollings Cancer Center
    Charleston, South Carolina 29407, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Utah - Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • HENRY DUNANT Hospital Center, 4th Department of Medical Oncology and Clinical Trials Unit
    Athens, 11526, Greece
  • Metropolitan Hospital "Perseus Healthcare Group SA" 4th Oncology Department
    Piraeus, 18547, Greece
  • Bioclinic Thessaloniki, Οncology Department
    Thessaloniki, 54622, Greece
  • European Interbalkan Medical Center, Οncology Department
    Thessaloniki, 57001, Greece
  • Prince of Wales Hospital
    Hong Kong, Hong Kong
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Polish Mother's Memorial Hospital-Research Institute
    Lodz, Lodzkie 93-338, Poland
  • Beata Głogowska
    Tomaszów Mazowiecki, Lodzkie 97-200, Poland
  • Institute of Genetics and Immunology GENIM LCC in Lublin
    Lublin, Lubelskie 20-609, Poland
  • Malgorzata Kozlik
    Warsaw, Mazowieckie 08-781, Poland
  • MED-Polonia, Sp. z o.o. (LLC)
    Poznan, Wielkopolskie 60-693, Poland
  • University Hospital Nuestra Senora de Valme
    Sevilla, Andalusia 41014, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Catalonia 08041, Spain
  • Hospital del Mar
    Barcelona, Catalonia 089003, Spain
  • Anna Ramos Luna
    Barcelona, Catalonia 08908, Spain
  • University Clinic of Navarra - Madrid
    Madrid, 28027, Spain
  • University Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung City, Taiwan
  • National Cheng Kung University Hospital
    Tainan, Taiwan
  • National Taiwan University Hospital
    Taipei City, Taiwan
  • LinKou Chang Gung Memorial Hospital
    Taoyuan City, Taiwan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Dec 2024, 78 months.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 78 months is above that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2018
First posted
Apr 20, 2018
StartActual
Jun 27, 2018
Primary completionActual
Dec 30, 2024
CompletionActual
Dec 30, 2024
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03504488
Lead sponsor
BioAtla, Inc.
Responsible party
Sponsor
First posted
Apr 20, 2018
Start date
Jun 27, 2018
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024
Last update
Jan 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ozuriftamab vedotin

Start the discussion